BTK
Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 169 productos para "BTK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Fórmula:C25H23ClN4O4Pureza:98.68% - 99.63%Forma y color:SolidPeso molecular:478.93AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Fórmula:C33H31FN6O3Pureza:≥95%Forma y color:SolidPeso molecular:578.64IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Fórmula:C22H22N6OPureza:99.88% - 99.88%Forma y color:Yellow SolidPeso molecular:386.45Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Fórmula:C25H23ClN6O3Pureza:99.27% - 99.95%Forma y color:White SolidPeso molecular:490.94MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Fórmula:C41H41N9O8Pureza:95.93% - 97.60%Forma y color:SolidPeso molecular:787.82Ref: TM-T16157
1mg92,00€5mg177,00€1mL*10mM (DMSO)231,00€10mg269,00€25mg510,00€50mg692,00€100mg888,00€200mg1.251,00€Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Forma y color:White SolidPeso molecular:665.76Ref: TM-T12542
1mg94,00€5mg222,00€1mL*10mM (DMSO)325,00€10mg356,00€25mg620,00€50mg893,00€100mg1.251,00€500mg2.502,00€Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Fórmula:C24H25N5O3Pureza:99.94%Forma y color:SolidPeso molecular:431.49Ref: TM-T10629
1mg34,00€2mg49,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg98,00€25mg215,00€50mg356,00€100mg434,00€Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.Fórmula:C26H23N7O2Pureza:99.20%Forma y color:SolidPeso molecular:465.51Ref: TM-T67881
200mgA consultar1mg80,00€5mg168,00€1mL*10mM (DMSO)178,00€10mg238,00€25mg379,00€50mg513,00€100mg707,00€Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Fórmula:C26H25N3O3Pureza:97.77% - 99.54%Forma y color:SolidPeso molecular:427.49Ref: TM-T12317
1mg86,00€5mg177,00€1mL*10mM (DMSO)205,00€10mg299,00€25mg492,00€50mg682,00€100mg897,00€500mg1.791,00€SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Fórmula:C41H45ClN8O7Pureza:98%Forma y color:SolidPeso molecular:797.3LFM-A13
CAS:LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.Fórmula:C11H8Br2N2O2Pureza:99.50%Forma y color:White SolidPeso molecular:360CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Fórmula:C48H68N10O9SPureza:98%Forma y color:SolidPeso molecular:961.18BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Fórmula:C23H23ClFN7O2Forma y color:SolidPeso molecular:483.93DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Fórmula:C55H62N10O8Forma y color:SolidPeso molecular:991.163PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Forma y color:Odour SolidGBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Fórmula:C44H47N9O6Pureza:98%Forma y color:SolidPeso molecular:797.9Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Fórmula:C43H43N9O4Forma y color:SolidPeso molecular:749.86Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Fórmula:C8H6BrN3SPureza:99.94%Forma y color:White SolidPeso molecular:256.12
